TransMedics Group (NASDAQ:TMDX) Insider Anil Ranganath Sells 864 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil Ranganath sold 864 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $120,199.68. Following the transaction, the insider owned 13,091 shares of the company’s stock, valued at approximately $1,821,219.92. This trade represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

TransMedics Group Stock Down 0.2%

Shares of NASDAQ:TMDX traded down $0.34 during midday trading on Wednesday, reaching $147.66. The company had a trading volume of 701,764 shares, compared to its average volume of 830,019. The stock has a market capitalization of $5.06 billion, a P/E ratio of 30.13 and a beta of 1.98. The stock’s fifty day moving average price is $134.97 and its 200-day moving average price is $126.78. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. TransMedics Group, Inc. has a one year low of $62.07 and a one year high of $156.00.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. bought a new position in shares of TransMedics Group in the fourth quarter valued at approximately $162,000. Virtu Financial LLC lifted its position in TransMedics Group by 467.7% in the fourth quarter. Virtu Financial LLC now owns 26,949 shares of the company’s stock worth $3,278,000 after purchasing an additional 22,202 shares during the period. Corient Private Wealth LLC boosted its stake in TransMedics Group by 32.5% during the 4th quarter. Corient Private Wealth LLC now owns 3,084 shares of the company’s stock valued at $375,000 after purchasing an additional 757 shares in the last quarter. Summit Global Investments increased its position in shares of TransMedics Group by 3.6% during the 4th quarter. Summit Global Investments now owns 3,260 shares of the company’s stock valued at $397,000 after purchasing an additional 112 shares during the period. Finally, EP Wealth Advisors LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth $210,000. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Canaccord Genuity Group lifted their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Morgan Stanley lifted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Piper Sandler increased their target price on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Oppenheimer raised their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.